ChinaMart

China Biotech Week in Review: Earnings, Deals and Drug Development

LTUS (Lotus Pharmaceuticals) reaffirmed 2008 guidance on Friday. That guidance of $13.8M USD in net income is about .29/share fully diluted...making the PE for LTUS well under 4.
As far as I can tell, this makes LTUS the best value in the China Biopharma sector today.